274 related articles for article (PubMed ID: 9447815)
21. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia.
Lopingco MC; Perkins AS
Curr Top Microbiol Immunol; 1996; 211():211-22. PubMed ID: 8585952
[TBL] [Abstract][Full Text] [Related]
23. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
Mitani K; Ogawa S; Tanaka T; Miyoshi H; Kurokawa M; Mano H; Yazaki Y; Ohki M; Hirai H
EMBO J; 1994 Feb; 13(3):504-10. PubMed ID: 8313895
[TBL] [Abstract][Full Text] [Related]
24. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
25. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.
De Braekeleer M; Le Bris MJ; De Braekeleer E; Basinko A; Morel F; Douet-Guilbert N
Future Oncol; 2015; 11(11):1675-86. PubMed ID: 26043219
[TBL] [Abstract][Full Text] [Related]
26. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.
Peeters P; Wlodarska I; Baens M; Criel A; Selleslag D; Hagemeijer A; Van den Berghe H; Marynen P
Cancer Res; 1997 Feb; 57(4):564-9. PubMed ID: 9044825
[TBL] [Abstract][Full Text] [Related]
27. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1044-8. PubMed ID: 8577711
[TBL] [Abstract][Full Text] [Related]
28. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
[TBL] [Abstract][Full Text] [Related]
29. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8).
Suzukawa K; Kodera T; Shimizu S; Nagasawa T; Asou H; Kamada N; Taniwaki M; Yokota J; Morishita K
Leukemia; 1999 Sep; 13(9):1359-66. PubMed ID: 10482986
[TBL] [Abstract][Full Text] [Related]
30. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
31. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
32. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
33. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
[TBL] [Abstract][Full Text] [Related]
34. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
[TBL] [Abstract][Full Text] [Related]
35. EVI1 in Leukemia and Solid Tumors.
Liang B; Wang J
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962037
[TBL] [Abstract][Full Text] [Related]
36. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
37. [Advances in the study of Evi1 and mds1 genes].
Xu K; Wang L; Hao Y
Zhonghua Xue Ye Xue Za Zhi; 1999 Jun; 20(6):331-3. PubMed ID: 11721391
[No Abstract] [Full Text] [Related]
38. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
39. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
[TBL] [Abstract][Full Text] [Related]
40. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Löwenberg B; Delwel R
Exp Hematol; 2003 Nov; 31(11):1066-72. PubMed ID: 14585371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]